May 14, 2020
FDA accelerates development of COVID-19 prevention, treatment options
Editor's Note
The Food & Drug Administration on May 11 took new actions to accelerate the development of novel prevention and treatment options for COVID-19.
The agency is providing guidance documents to make the process for submitting applications to initiate studies for new drugs and biological products more efficient.
The documents also outline recommendations for ways to design clinical trials to evaluate safety and effectiveness of these products for COVID-19.
Free Daily News
- Milestone pig kidney transplant offers hope amid ethical, safety questions
- Fitch Ratings: Hospital credit outlook improves amid stabilizing margins
- Annual Leapfrog Group awards recognize top hospitals, ASCs
- US obesity rates decline for first time in a decade
- Study: Active monitoring without surgery safe for certain low-risk DCIS patients
- Data support option to skip sentinel lymph node biopsy in early breast cancer
- Surveyed nurses, physicians likely to quit
- Costs drop, access expands for GLP-1 weight loss drugs
- Q&A: Perioperative immunotherapy advances for early-stage NSCLC
- Proposals close December 16: Present at the 2025 OR Manager Conference
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement